These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28612430)

  • 1. IgG subclasses of FVIII inhibitors in an argentine cohort of severe hemophilia A patients: Analysis by flow cytometry.
    Irigoyen MB; Primiani L; Felippo M; Candela M; de Bracco MME; Galassi NV
    Int J Lab Hematol; 2017 Dec; 39(6):569-576. PubMed ID: 28612430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
    Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM
    Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Sep; 21(5):686-92. PubMed ID: 25708525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
    Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
    J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients.
    Reding MT; Lei S; Lei H; Green D; Gill J; Conti-Fine BM
    Thromb Haemost; 2002 Oct; 88(4):568-75. PubMed ID: 12362225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors.
    Hofbauer CJ; Kepa S; Schemper M; Quehenberger P; Reitter-Pfoertner S; Mannhalter C; Reipert BM; Pabinger I
    Blood; 2016 Jul; 128(2):293-6. PubMed ID: 27216215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
    Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
    Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.
    Irigoyen MB; Primiani L; Felippo M; Candela M; Bianco RP; De Bracco MM; Galassi N
    Haemophilia; 2011 Mar; 17(2):267-74. PubMed ID: 21070488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.
    Miller CH; Rice AS; Boylan B; Payne AB; Kelly FM; Escobar MA; Gill J; Leissinger C; Soucie JM;
    Am J Hematol; 2015 Oct; 90(10):871-6. PubMed ID: 26147783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.
    Paul H; Berg V; Gangadharan B; Bowen J; LeBeau P; Blatný J; Male C; Radulescu VC; Diaz R; Mancuso ME; Brown DL; Reipert BM
    Blood Adv; 2023 May; 7(9):1831-1848. PubMed ID: 36074992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy.
    Yoshimura T; Furukawa S; Oda A; Matsumoto T; Sasai K; Shima M; Nogami K
    Int J Hematol; 2022 Sep; 116(3):423-433. PubMed ID: 35503593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicohematologic Profile of Patients With Factor VIII Inhibitors: A Case Series.
    Singh N; Mishra P; Tyagi S; Pati HP; Mahapatra M; Seth T; Saxena R
    Clin Appl Thromb Hemost; 2015 Apr; 21(3):246-50. PubMed ID: 25172870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating FVIII-specific IgG, IgA and IgM memory B cells from haemophilia A patients.
    Diaz I; Bolloré K; Tuaillon E; Lapalud P; Giansily-Blaizot M; Vendrell JP; Schved JF; Lavigne-Lissalde G
    Haemophilia; 2016 Sep; 22(5):799-805. PubMed ID: 27439547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.
    Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Donfield SM; Astermark J; Berntorp E; Lollar P; Schwabe D; Königs C
    Haemophilia; 2017 Mar; 23(2):292-299. PubMed ID: 27862687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies.
    Sahud M; Zhukov O; Mo K; Popov J; Dlott J
    Haemophilia; 2012 Sep; 18(5):777-81. PubMed ID: 22458845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
    Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
    J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.